MNK, BMY, BLUE Stocks On the Move Today

A lack of clarity over its lung cancer treatment has Bristol-Myers Squibb shares tumbling

Jun 5, 2017 at 2:09 PM
facebook X logo linkedin

It's a mixed trading session on Wall Street today, though the Nasdaq Composite (COMP) hit a record high earlier. Among names making big moves are healthcare stocks Mallinckrodt PLC (NYSE:MNK), Bristol-Myers Squibb Co (NYSE:BMY), and bluebird bio Inc (NASDAQ:BLUE). Here's a quick look at what's moving shares of MNK, BMY, and BLUE.

MNK Stock Sinks After Latest Citron Research Swipe

MNK stock is trading down 5.1% at $40.47 -- the biggest decliner on the S&P 500 Index (SPX) -- following scathing words from Citron Research. The noted short seller said the stock is "on its way to zero," after an Express Scripts executive called Mallinckrodt's H.P. Acthar Gel "vastly overpriced for the value."  In addition, the Citron report compares Mallinckrodt to Enron.

Citron initially unveiled a short MNK position in 2015, and last November accused the drugmaker of "committing securities fraud." And though the stock is down 40% since its Nov. 15 close, not a single one of the 13 analysts covering Mallinckrodt stock maintain a "sell" recommendation. This leaves the door wide open for downgrades, which could pressure MNK shares even lower.

BMY Stock Sinks After ASCO Disappointment

Bristol-Myers Squibb stock is also near the bottom of the SPX, down 4.5% at $52.51. The company presented an update for its Opdivo-Yervoy combination lung cancer treatment at the American Society of Clinical Oncology's (ASCO) annual meeting, but analysts weren't impressed, with Barclays and Credit Suisse highlighting a lack of clarity.

While BMY stock has faced increasing pressure from its 200-day moving average for most of the last 12 months, the shares are now trading below their negative 10% year-to-date mark. Against this backdrop, short-term Bristol-Myers Squibb options traders are more put-heavy now than they've been at any other point over the past year, per the stock's Schaffer's put/call open interest ratio (SOIR) of 0.90 -- an annual high.

BLUE Stock is Ripe for a Short Squeeze 

Celgene and bluebird bio gave an update on their joint multiple myeloma treatment, bb2121, at ASCO, sending BLUE shares up 10.1% to trade at $92.62. This positive price action is just more of the same for bluebird bio stock, which is boasting a nearly 51% year-to-date lead. BLUE stock is a prime candidate for a short squeeze, too, considering 19.3% of its float is sold short, or 14 times the average daily pace of trading.


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI